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Summary
Although adult human cartilage is physiologically avascular tissue, angiogenesis can be observed during the process of endochondral bone
development. Inﬂammation in articular joints can also lead to neovascularization in cartilage. In such conditions, the expression of angiogenic
factors, such as vascular endothelial growth factor (VEGF), has been shown to play a key role, controlling not only angiogenesis but also
chondrocyte metabolism. Here we review recent research ﬁndings concerning the potential role of VEGF in cartilage, focusing in particular
on its possible involvement in the pathogenesis of osteoarthritis.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Being composed of a network of extracellular matrices and
scattered chondrocytes, mature articular chondrocytes in
physiological condition are essentially devoid of vascular
structure. Speciﬁcally, the proliferative and hypertrophic
zones in the growth plate are not penetrated by vascular
supply (Fig. 1)1, leaving chondrocytes in these zones in
an avascular milieu. The mechanisms by which mature ar-
ticular cartilage might be maintained as avascular have not
been fully clariﬁed. However, as cartilage is suggested to be
an enriched source of endogenous inhibitors of angiogene-
sis2, an array of anti-angiogenic factors has been identiﬁed.
For example, Moses et al. identiﬁed Troponin I (TnI) in car-
tilage, which is known as a contractile protein expressed in
muscle2. In this study, TnI was shown to inhibit proliferation
of capillary endothelial cells and embryonic angiogenesis in
vivo, thus indicating the anti-angiogenic potential of TnI. In
addition, a 25-kD glycoprotein, chondromodulin-I (ChM-I)
was reported to play an important role in the resistance of
cartilage to angiogenesis (reviewed in Ref. 3). As for
ChM-I, Shukunami et al. demonstrated that the level of
ChM transcript was maintained at a high level in the avas-
cular zones of bone rudiments, including the resting, prolif-
erating and early hypertrophic zones. In contrast, the ChM
expression was abolished in the lower hypertrophic and cal-
ciﬁed zones of cartilage, allowing vascular invasion to result
in the initiation of endochondral bone formation3.*Address correspondence and reprint requests to: Dr Kayo
Masuko, M.D., Ph.D., Department of Biochemistry, St. Marianna
University School of Medicine, Kawasaki 216-8511, Japan. Tel:
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279Despite this anti-angiogenic machinery occurring in carti-
lage, recent studies have revealed the important contribu-
tion made by a variety of pro-angiogenic factors in the
cartilage metabolism, including vascular endothelial growth
factor (VEGF). Here we review some recent reports on the
representative angiogenesis-regulating factor (VEGF),
focusing on its possible implication in the pathogenesis of
osteoarthritis (OA).VEGF
VEGF is known to be an important mediator of angiogen-
esis. The VEGF family comprises at least seven members:
VEGF/VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E,
VEGF-F and placental growth factor (PIGF)4e6. VEGF-A
is often referred to as simply VEGF7, is encoded by the
Vegf/Vegf-A gene, which generates at least ﬁve isoforms
of VEGF through alternative splicing. VEGF189 and
VEGF206, which differ in their binding to the extracellular
matrix and to the receptors4,8. In addition, recent studies
have suggested that the selection of an alternate splice
site may result in the generation of a sister family of iso-
forms, i.e., anti-angiogenic VEGF-A isoforms (VEGF***b;
e.g., VEGF165b), in addition to pro-angiogenic isoforms
(VEGF***)
7.
Within the VEGF family, VEGF-A is the founding member
and is thought to be of singular importance4. VEGF-B,
VEGF-C, VEGF-D, VEGF-E, VEGF-F and PIGF share
amino acid sequence homology with VEGF/VEGF-A and
may have been classiﬁed as ‘‘VEGF-related proteins’’9.
Since most previous studies on VEGF in regard to its ex-
pression in chondrocytes have focused on VEGF/VEGF-
A, and little is known about the involvement of other
VEGF families, we hereafter focus on VEGF-A as the class
of VEGF referred to in this review article.
Fig. 1. Vascular supply in the growth plate (based on Ref. 1).
280 M. Murata et al.: Roles of VEGF in OAVEGF binds to surface tyrosine kinase receptors
VEGFR-1 (or fms-like tyrosine kinase-1 (Flt-1) from mouse)
and VEGFR-2 [or kinase domain region (KDR)/fetal liver ki-
nase-1 (Flk-1)] which are strongly expressed by endothelial
cells10. VEGFR-1 and VEGFR-2 are composed of seven
extracellular immunoglobulin (Ig)-like domains containing
the ligand-binding region, a short membrane-spanning
sequence, and a conserved intracellular tyrosine kinase
domain interrupted by a kinase insert sequence5,9,10.
VEGFR-1 has the highest afﬁnity for VEGF-A, and also binds
PIGF and VEGF-B, whereas VEGFR-2 would seem to bind
VEGF-C, VEGF-D, VEGF-E and VEGF-F, as well as
VEGF-A5,9. VEGFR-1 and VEGFR-2 are structurally similar
and share 43.2% sequence homology; more speciﬁcally, the
extracellular domain displays 33.3% homology and the cyto-
plasmic region shares 54.6%between the two receptors10,11.
Neuropilin-1, a receptor for semaphorins found in the nerve
system, has also been found to bind VEGF4,5,12. VEGF-C
and VEGF-D are known to bind to VEGFR-3, but binding of
VEGF/VEGF-A to VEGFR-3 has not been found5,9.
Evidence has revealed that the binding of VEGF to
VEGFR leads to VEGF-induced angiogenesis, mitogenesis
and cell survival (reviewed in Refs. 8,10). Under physiolog-
ical conditions, a healthy adult organism does not exhibit
any active angiogenic process, with the exception of
a few cases, including that of the female reproductive sys-
tem, in which hormonal regulation would appear to play
a role also in the expression of VEGF and VEGFR13,14.
VEGF expression is also detectable in certain adult organs
and cell types, such as lung, kidney, liver and brain10.
Expression of VEGF and subsequent angiogenesis is, on
the other hand, an important process during tissue repair
such as that of a fracture. For example, Street et al.15 re-
ported that the inhibition of VEGF using a soluble, neutral-
izing VEGF receptor impaired fracture repair in mice,
while treatment with exogeneous VEGF promoted fracturerepair as well as angiogenesis. The authors suggested
that osteoblast played a role in the VEGF-mediated bone
repairing mechanism15.Endochondral bone development and VEGF
Endochondral bone development is a complex process in
which ordered phases of proliferation, maturation and apo-
ptosis of chondrocytes occur in growth plate chondrocytes
(reviewed in Ref. 16). Speciﬁcally, in immature skeleton,
the growth plate is composed of three histologically distinct
zones: reserve, proliferative, and hypertrophic (Fig. 1).
Chondrocytes in the proliferative zone synthesize type II
collagen; and after termination of proliferation, cells differen-
tiate into hypertrophic chondrocytes that express type X col-
lagen and produce alkaline phosphatase. The hypertrophic
chondrocytes then mineralize the matrix, replacing the car-
tilaginous matrix with trabecular bone.
During this process, the growth plate allows distinct vas-
cular supplies. More speciﬁcally, the epiphyseal artery
enters the secondary center of ossiﬁcation and its terminal
branches terminate at the uppermost part of the proliferative
zone. These vessels do not penetrate into the proliferative
or hypertrophic zone. On the other hand, the metaphyseal
artery enters at the mid-diaphysis and sends branches to
each metaphysis without penetrating into the hypertrophic
zone of the growth plate.
In regard to cartilage vascularization, Gerber et al.17 clar-
iﬁed the essential role of VEGF in endochondral bone
development by inactivating VEGF in systemic administra-
tion of a soluble receptor chimeric protein to mice. The
results of the inhibition of VEGF activity showed impaired
bone formation and the expansion of hypertrophic chondro-
cytes, along with an almost complete suppression of blood
vessel invasion. The authors concluded that VEGF-mediated
281Osteoarthritis and Cartilage Vol. 16, No. 3vascularization is an essential signal to regulate growth
plate morphogenesis through the induction of coupling re-
sorption of cartilage with bone formation.
The important role of VEGF in cartilage vascularization
and in bone development has been supported by other pa-
pers18e21. For example, Zelzer et al. generated mice lack-
ing the VEGF gene (Vegf-A) in chondrocytes using
a chondrocyte-speciﬁc promoter Col2a1, along with the
Cre-loxP system20. The Vegf-A knockout mice showed im-
paired embryonic bone development, reduced angiogene-
sis, and reduced removal of terminally differentiated
hypertrophic chondrocytes. There were also areas of mas-
sive cell death in the center of the bones of the Vegf-A
knockout mice, suggesting that VEGF plays an essential
role in chondrocyte survival during endochondral bone for-
mation. Evidence of VEGF expression has also been found
in human neonatal cartilage22,23, indicating its potential im-
plication in bone development in humans as well (Fig. 2).Factors that induce VEGF expressionHYPOXIA AND HYPOXIA-INDUCIBLE FACTOR (HIF)-1In the growth plate, oxygen tension in the reserve, prolif-
erative and hypertrophic zones has been reported to be
20.5 2.1, 57 5.8 and 29.3 2.4 mmHg, respectively1.
Low oxygen in the reserve and hypertrophic zones is attrib-
utable to the lack of supply through vascularity.
It has been established that the hypoxia is a prime stim-
ulus for angiogenesis24. More speciﬁcally, reduced oxygen
tension induces expression of VEGF through induction of
a transcription factor, HIF-1a. Speciﬁcally, HIF-1a leads toFig. 2. Hypothetical kinetics of VEGF expression in human articular cho
VEGF is expressed in chondrocytes playing a pivotal role in cartilage gr
phase’’), expression of angiogenic factors is suppressed and blood vess
cartilage avascular. Upon exposure to pathological stimulation such as
re-upregulated in hypertrophic chondrocytes. Although the fate of VEGF ex
levels of VEGF expression in OA than in normal chondrocytes have been
shown in the dtranscriptional activation of the VEGF gene in hypoxic cells
by binding to a hypoxia response element (HRE) located
1 kb 50 to the transcription initiation site25,26. A strong induc-
tion of VEGF by HIF-1a has been revealed in a wide range
of tissues (Fig. 3)5.
In this regard, accumulated data have revealed that HIF-
1a is a master regulator of the expression of various hyp-
oxia-induced genes. The target genes of HIF-1 are related
not only to angiogenesis, but also to cell proliferation/sur-
vival, and glucose/iron metabolism27. Moreover, activation
of HIF-1a has been closely associated with a variety of
different tumors and oncogenic pathways27.
With regard to the implication of hypoxia in arthritic condi-
tions, hypoxic stress is thought to be one of the inﬂamma-
tion-modulating factors in articular joints. Speciﬁcally,
a major survey in 1970 by Lund-Olesen reported that the
mean oxygen tension (PO2) in synovial ﬁbroblasts (SF) of
rheumatoid arthritis (RA) patients (27 mmHg) was signiﬁ-
cantly lower than in cases of acute traumatic effusion
(63 mmHg). Knee SF from OA patients was also more hyp-
oxic (mean 43 mmHg)28. These ﬁndings suggested that ar-
ticular chondrocytes in inﬂammatory joints were supplied
with lower levels of oxygen than under healthy conditions.
Consistent with the hypoxic condition of joints, it has been
reported that expression of HIF-1a is upregulated in syno-
vial cells of RA and in OA (Refs. 29,30, reviewed in Refs.
31,32). Giatromanolaki et al. showed that the high HIF-1a
expression in OA synovial cells was associated with
increased expression of ‘‘activated microvessel density
(MVD)’’ assessed with positive staining of antibody 11B5,
which stained VEGF bound to its receptor KDR30. They
suggested that within the degenerative context of OA,ndrocytes. During growth plate development (‘‘the growth phase’’),
owth and endochondral ossiﬁcation. In adult cartilage (‘‘the mature
el invasion is also almost completely suppressed, leaving mature
inﬂammation or accumulating mechanical stress, VEGF would be
pression in stressed chondrocytes has always been unclear, higher
reported. Arbitrary levels of VEGF expression in chondrocytes are
rawing.
Fig. 3. The potential role of VEGF in OA (hypothesis). VEGF could be induced by an array of catabolic triggers in chondrocytes, and the
expressed VEGF might affect these chondrocytes, e.g., via angiogenesis leading to osteophyte formation, via induction of matrix proteases,
or via regulation of cellular viability through Bcl-2 activation.
282 M. Murata et al.: Roles of VEGF in OAimpaired vascular homeostasis may result in focal, expand-
ing hypoxic regions in the synovium, and that upregulation
of HIF-1a together with resultant VEGF overexpression
would lead to the genesis of a defective vascular network
with poor survival ability, which would be consistent with
the degenerative nature of OA. On the other hand, the
same study demonstrated that in RA VEGF/KDR activation,
MVD and expression of platelet-derived endothelial cell
growth factor (PD-ECGF) did not depend on HIF-1a expres-
sion. The authors hypothesized that angiogenesis may not
depend on the HIF reactivity and that hypoxia may not be
the only up-regulating factor of the HIF/VEGF pathway in
RA. Rather, inﬂammatory factors, such as interleukin-1
(IL-1) of tumor necrosis factor a (TNFa), may directly stim-
ulate the VEGF or PD-ECGF overexpression in RA. It is
therefore suggested that angiogenesis follows different
pathogenic pathways in OA and RA30.
As for the role of HIF-1a in cartilage, Schipani et al.33 re-
ported in 2001 that HIF-1a is essential for chondrocyte
growth survival. In that paper, the authors developed mice
lacking HIF-1a in growth plate chondrocytes, and showed
that the lack of HIF-1a did not severely alter the differentia-
tion process of chondrocytes per se. There was, however,
a massive cell death in mutant growth plate chondrocytes
indicating a requisite of HIF-1a for the survival of hypoxic
chondrocytes33,34. Additional reports, including our own35
and those of others36, demonstrated the role of HIF-1a in
cartilage matrix production. Speciﬁcally, we observed that
HIF-1a-deﬁcient chondrocytes did not maintain energy gen-
eration or cartilage matrix production under either normoxic
or hypoxic conditions35. Furthermore, HIF-1a-deﬁcient
chondrocytes showed an acceleration of catabolic stress-
induced apoptosis in vitro35. Taken together, low oxygen
tension, or hypoxia, in inﬂamed synovial joints appears toevoke activation of HIF-1a, followed by expression of
a plethora of downstream molecules including VEGF, that
collectively alters the chondrocyte metabolism, possibly
toward a catabolic response, hence modulating the patho-
physiology of arthropathies.MECHANICAL STRESSIt has been recognized that excessive mechanical stress,
such as compression or shear, would cause deterioration of
the cartilage metabolism through induction of catabolic fac-
tors, including matrix metalloproteinases (MMPs)37e41. In
this regard, involvement of VEGF in the mechanical
stress-induced cartilage degradation has been the subject
of investigation. Speciﬁcally, Pufe et al. reported the effect
of mechanical overload on VEGF expression in bovine car-
tilage disks42. The team demonstrated VEGF expression in
overloaded disks but not in control disks. The overload-
induced VEGF expression was accompanied by HIF-1a ex-
pression and also by co-expression of MMPs, suggesting
that VEGF played a role in the destruction of stressed car-
tilage. In fact, the authors also reported expression of VEGF
in the superﬁcial zone of the tibial plateau in OA patients
with degenerative changes, but not in healthy cartilage43.
Although it is possible that VEGF exists in the deeper carti-
lage zones at below detectable levels, the predominance of
VEGF in the superﬁcial zone would appear to support
enhanced expression after mechanical loading.
Of note, ‘‘mechanical stress’’ is usually composed of
a complex mixture of tension, shear, compression and
strain; and since each component might differentially regu-
late gene expression, the response in vivo would not be as
simple as was observed in the in vitro experiments. Wong
et al.44, employing chondrocytes cultured in alginate beads,
283Osteoarthritis and Cartilage Vol. 16, No. 3assessed VEGF expression and found that the principal ef-
fect of hydrostatic pressure (HP) was to downregulate
MMP-13 and type I collagen, while up-regulating tissue in-
hibitor of metalloproteinases (TIMP)-1. In their paper, the
authors showed that VEGF was signiﬁcantly upregulated
by both cyclic tension and HP44. In any case, as Loeser
suggested, abnormal mechanical stress might ‘‘awaken’’
the adult chondrocytes from low metabolic activity and stim-
ulate each cell to produce inﬂammatory mediators, includ-
ing VEGF, which increases the catabolic activity of
chondrocytes41.MISCELLANEOUSThere are variety of other factors that are potent enough to
induce VEGF (reviewed in Ref. 10); for example, IL-1, IL-17,
TNFa, nitric oxide (NO) and reactive oxygen species (ROS)
haveall been reported to induceVEGFexpression in cultured
chondrocytes8,45e47. For example, in a study by Honorati
et al. it was suggested that IL-1bwasmore potent in inducing
VEGF in cultured OA chondrocytes than IL-17 or TNFa46.
These mediators may utilize different signaling pathways to
elicit VEGF expression, since we found that distinct signaling
pathways are involved in hypoxia- and IL-1-induced VEGF
expression in articular chondrocytes47. Kanata et al. recently
demonstrated that a binding of oxidized low-density lipopro-
tein (ox-LDL) to lectin-like ox-LDL receptor-1 (LOX-1) upre-
gulates VEGF expression in chondrocytes, suggesting that
peroxisome proliferators-activated receptor (PPAR)-g acti-
vation plays a role in this process48.
It has been reported that ROS enhanced VEGF expres-
sion, including that in chondrocytes49. In this regard, a paper
by Tomiyama et al. demonstrated that mechanical com-
pression of articular cartilage induced ROS synthesis,
whereas it inhibited proteoglycan synthesis50. Furthermore,
Green et al. observed that impact injury led to chondrocyte
death, even at a distant site from the injury, through the gen-
eration of NO51. Considering these ﬁndings together, it
might be that mechanical stress induces ROS as a ﬁrst re-
sponse, and that factors such as VEGF are mobilized as
a next step, altogether affecting chondrocyte viability and
the cartilage metabolism41.
Besides this, in experimental systems, sodium arsenite is
also used to induce VEGF expression52,53. The arsenite-in-
duced VEGF expression was reported to be mediated not
by HIF-1, but rather by p38 Mitogen activated protein kinase
(MAPK)52.Outcome of VEGF expression in
cartilagedimplications in OA?
Although theVEGF/VEGFRexpression is critical in neona-
tal endochondral bone development, it is generally not found
in adult human articular cartilage under physiological condi-
tions18,54. Nevertheless, recent investigations have revealed
expression of VEGF and its receptors in diseased cartilage,
such as that of RA and OA (Fig. 2). For example, chondro-
cytes and cartilage tissue obtained from OA patients wereTable
Summary of the potential bioactivities of VEGF on
MMP-1 MMP-3 TMP-1/-2
Enomoto et al.57 [ [ / MMP-2,-9,-1
Pufe et al.42 [ [ Y IL-1, Il-6: [;
Pufe et al.63 [ [ Y MMP-13: [reported to express VEGF and VEGF receptors to a higher
degree than that found in healthy individuals55e58. Expres-
sion of VEGF was also found in OA synovium accompanied
by angiogenesis and inﬂammation59. Nevertheless, the pre-
cise mechanism by which VEGF might be involved in the
pathogenesis of OA is not clearly understood.OSTEOPHYTES AND VEGFOsteophytes are bony and cartilaginous structures in OA,
which arise from the bony margins of the osseous compo-
nents of the joint60. The formation of osteophytes has
been interpreted as an adaptation of the joint to the altered
biomechanics of OA joints61. In this connection, Hashimoto
et al. reported that hypertrophic chondrocytes in osteo-
phytes expressed VEGF after immunohistochemistry was
used on experimental OA animals61. They suggested that
VEGF plays a role in angiogenesis during osteophyte
development; however, the precise mechanism by which
VEGF might regulate osteophytes during OA development
is still unclear.INDUCTION OF MATRIX-DEGRADING CATABOLIC
FACTORS BY VEGFSeveral reports have hypothesized that VEGF might
induce expression and production of proteinases that
degrade extracellular matrix in vitro (Table I and reviewed
in Ref. 62). For example, in a study by Enomoto et al. the
authors incubated OA or normal chondrocytes with re-
combinant VEGF165 protein (at 0, 10, or 50 ng/ml), and
measured the levels of MMPs and TIMPs in the culture
supernatants. The results showed that the recombinant
VEGF165 increased the production levels of MMP-1 and
MMP-3 in OA chondrocytes, but not in normal chondro-
cytes. On the other hand, Pufe et al.63 cultured immortalized
human chondrocytic C28/I2 cells with recombinant
VEGF165 (10 ng/ml), and also showed a slight but signiﬁ-
cant increase in MMP levels. However, the increases in
MMP-1 and MMP-3 shown in these experiments by VEGF
were approx. 120e140% compared to samples without
VEGF treatment (as 100%) even after 3 days’ culture57,
and our experiments using OA, RA and normal samples
did not show any signiﬁcant increase in these MMPs, sug-
gesting varied responsiveness to VEGF among patients
and cells (Ref. 47, data not shown).
On the other hand, VEGF may have a synergistic role in
regulating gene expression of catabolic mediators. Komiya
et al.64 using RA SF showed that VEGFR-2 expressing RA
SF expressed higher levels of metalloproteinase ADAM
(a disintegrin and metalloproteinase)-15 when treated se-
quentially with TNFa and VEGF165, but not when stimulated
by TNFa or VEGF165 alone.REGULATION OF CELL GROWTH AND APOPTOSIS BY VEGFThe important role played by VEGF in chondrocyte devel-
opment and survival during bone development is borne outI
cartilage. [: upregulate and Y: downregulate
Others Source of chondrocytes
3:/ OA chondrocytes
MMP-13, TNFa, NO2: [ Human chondrocyte cell line C28/12
Bovine cartilage disks
284 M. Murata et al.: Roles of VEGF in OAby accumulating evidence20,21. It has also been suggested
that apoptotic chondrocyte death plays a role in matrix
breakdown in arthritis, including RA and OA, although the
debate about the ‘‘apoptosis’’ of chondrocytes in OA has
caused considerable controversy65. In this regard, Aigner
et al.66 have suggested in a recent comprehensive review
that in the majority of cases OA chondrocytes might not un-
dergo classical (apoptotic) cell death and remain viable, but
instead degenerate as dysfunctional remnants. Further-
more, the precise mechanisms by which HIF-1a/VEGF-
mediated signaling might be involved in apoptotic cell death
in human OA have not been fully clariﬁed.
It has been reported that VEGF promotes cell survival by
inducing the expression of anti-apoptotic molecules such as
Bcl-25,67,68. In this context, some reports have suggested
that Bcl-2 plays a role in regulation of chondrocyte apopto-
sis in OA69e72, and further in regulation of matrix gene
expression through Sox973,74. For example, Kim et al.
reported that Bcl-2 expression in normal cartilage was sig-
niﬁcantly higher than in OA cartilage, suggesting the in-
volvement of Bcl-2 in OA pathogenesis69. Furthermore,
a recent study by Surendran et al.72 showed that Bcl-2-
transfected chondrocytes were protected from NO-induced
impairment of proteoglycan synthesis, implying the possible
value of Bcl-2 gene therapy in arthritis72. However, there
has been no direct data to show the cell proliferating effect,
or the upregulation of Bcl-2 expression by VEGF in human
OA chondrocytes, and this issue awaits further
investigation.VEGF IN OA: A POTENTIAL THERAPEUTIC TARGET?As described, there is evidence of higher levels of VEGF
expression in OA chondrocytes than in nonarthritic chon-
drocytes. Thus VEGF might, at least in part, be participating
in the pathophysiology of cartilage degeneration in OA. Tar-
geting VEGF in OA could be beneﬁcial for the suppression
of osteophyte formation and/or downregulation of MMP pro-
duction. The observations that VEGF might upregulate the
expression of anti-apoptotic Bcl-2, and that apoptotic cell
death has been suggested in OA (causing some contro-
versy), seem to be inconsistent. However, as recent studies
have suggested the occurrence of ‘‘senescence’’ or prema-
ture chondrocytes during aging as an important trigger of
OA pathogenesis66,75, cell death or degeneration of
chondrocytes might already be in process when VEGF is
re-upregulated by the stress trigger (Fig. 2). In these circum-
stances, suppression of VEGF could be a target of OA ther-
apy, not as an anti-apoptotic but rather an ‘‘anti-inﬂammatory’’
strategy, since it has been suggested that OA is an inﬂamma-
tory disease76,77. The potential effect (either direct or HIF-
1-mediated) of VEGF on the metabolism of extracellular
matrix components, such as collagens and proteoglycan, or
in the cellular senescence of mature articular chondrocytes,
should be further investigated.Concluding remarks: not only angiogenesis,
but more
Accumulating data are unveiling the importance of VEGF
in physiological angiogenesis, as well as in growth plate de-
velopment and endochondral ossiﬁcation. However, it may
still not be fully understood when and how the angiogenic
factor is activated or functions in articular cartilage during
aging, or in pathological situations such as arthritides. Tar-
geting angiogenic factors, including VEGF, might open upa novel avenue toward establishing therapeutic strategies
against cartilage degradation in OA.References
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